ReviewCurrent treatment options in neurology2017
Treatment of Sleep Dysfunction in Parkinson's Disease.
Review in Current treatment options in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Pharmacological treatment of sleep disorder phenotypes in Parkinson's disease: a systematic review and meta-analysis of randomised controlled trials.Journal of neurology · 2026Pooled it
- Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2020Trial
- A Sensorimotor Framework for the Neurorehabilitation of Oculomotor Dysfunction in Parkinson's Disease.Journal of clinical medicine · 2026Review
- Demographic and Clinical Characteristics of Hospitalized Patients with Type 2 Diabetes Mellitus and Comorbid Parkinson's Disease in Spain: A Nationwide Observational Study (2017-2023).Journal of clinical medicine · 2025Article
- Review
- Sleep-Related Disorders in Parkinson's Disease: Mechanisms, Diagnosis, and Therapeutic Approaches.CNS & neurological disorders drug targets · 2025Review
- The Influence of Gender and Length of Therapy Use on Sleep Quality in Patients with Parkinson's Disease.Materia socio-medica · 2025Article
- Efficacy and exploratory analysis of potential mechanisms of stellate ganglion block in alleviating sleep disturbance in generalized anxiety disorder: a randomized controlled trial excluding comorbid depression.Frontiers in neurology · 2025Article
- Sleep Disturbance in Parkinson's Disease: Consequences for the Brain and Disease Progression - A Narrative Review.Nature and science of sleep · 2025Review
- The Impact of Fatigue on Sleep and Other Non-Motor Symptoms in Parkinson's Disease.Brain sciences · 2024Article
- Targeting sleep and the circadian system as a novel treatment strategy for Parkinson's disease.Journal of neurology · 2024Article
- Addressing Comorbidities in People with Parkinson's Disease: Considerations From An Expert Panel.Journal of Parkinson's disease · 2024Review
- Review
- Article
- Evaluation of Nocturnal Symptoms in Chinese Parkinson's Disease Patients Based on the PDSS-2 Scale: A Multicenter Cross-Sectional Study.Journal of Parkinson's disease · 2023Article
- Effects of exercise on sleep spindles in Parkinson's disease.Frontiers in rehabilitation sciences · 2022Article
- Article
- Circadian rhythms in neurodegenerative disorders.Nature reviews. Neurology · 2022Review
- Management of Sleep Disturbances in Parkinson's Disease.Journal of Parkinson's disease · 2022Review
- Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?BMC neurology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
opinion statementImpaired sleep and alertness affect the majority of Parkinson's disease (PD) patients, negatively impacting safety and quality of life. The etiology of impaired sleep-wake cycle in PD is multifactorial and encompasses medication side effects, nocturnal PD motor symptoms, and presence of co-existent sleep and neuropsychiatric disorders. The primary neurodegenerative process of PD involves brain regions that regulate the sleep-wake cycle, such as brainstem and hypothalamic nuclei. Sleep disorders in PD include insomnia, REM sleep behavior disorder (RBD), sleep disordered breathing (SDB), restless legs syndrome (RLS), and circadian disruption. Despite its high prevalence in the PD population, there is a paucity of clinical studies that have investigated treatment of sleep dysfunction associated with PD. Therefore, we aim to review available evidence and outline treatment strategies for improvement of disorders of sleep and wakefulness in PD patients. Evidence supporting the efficacy of pharmacological and non-pharmacological treatment strategies in PD is limited. There is thus a great need but also opportunity for development of well-designed clinical trials for impaired sleep and alertness in PD. Providing education about sleep hygiene and strategies for its implementation represents the initial step in management. Prompt diagnosis and treatment of co-existent primary sleep and psychiatric disorders are critical, as this may significantly improve sleep and alertness. While the optimal treatment for insomnia in PD has not been established, available strategies include cognitive-behavioral therapy, medications with soporific properties, and light therapy. Safety measures, clonazepam, and melatonin are the mainstay of treatment for RBD. Continuous positive airway pressure is an effective treatment for SDB in PD. The treatment algorithm for RLS associated with PD mirrors that used for idiopathic RLS. Circadian disruption has emerged as an important etiology of impaired sleep-wake cycles in PD, and circadian-based interventions hold promise for novel treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.